The JAMA article by Ryan et al1 on the association between biological therapies for psoriasis and cardiovascular events and the commentary by Bigby2 have generated significant controversy in the community of psoriasis researchers. By drawing attention to a potential increase in cardiovascular events in patients treated with interleukin (IL)-12/23 antagonists, the article and commentary provide a service to dermatologists and our patients.